Management of CMV infection and disease in transplant patients

Herpes

Volumn 11, Issue 3, 2004, Pages 77-86

  Razonable, Raymund R ^a   Emery, Vincent C ^b  

^a Mayo Clinic   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bone marrow transplant; Cytomegalovirus; Guidelines; Haematopoietic stem cell transplant; Recommendations; Solid organ transplant; Valganciclovir

Indexed keywords

ACICLOVIR; FOSCARNET; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR;

BLOOD ANALYSIS; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; LIVER TRANSPLANTATION; META ANALYSIS; NEUTROPENIA; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; OPPORTUNISTIC INFECTIONS; TRANSPLANTATION; VIRAL LOAD;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HERPES;

EID: 11244335482     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (69)

1. Griffiths PD, Whitley RJ (eds). Management Strategies in Herpes: The Challenge of CMV Infection and Disease in Transplantation. Worthing: PAREXEL MMS, 2001.
2. Mocarski ES. Cytomegaloviruses and their replication. In: Virology (Fields BN, Knipe DM, Howley PM, eds). Philadelphia: Lippincott-Raven, 1996 pp2447-2492.
3. Vancikova Z, Dvorak P. Cytomegalovirus infection in immunocompetent and immunocompromised individuals - a review. Gun-Drug Targets Immune Endocr Metabol Disord 2001;1: 179-187.
4. Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G et al. Allograft rejection predicts the occurrence of late-onset Cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184:1461-1464.
5. Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of Cytomegalovirus and Epstein-Barr virus infections. Herpes 2003:10:60-65.
6. Ljungman P. Cytomegalovirus infections in transplant patients. Scand J Infect Dis Suppl 1996;100:59-63.
7. Nichols WG, Boeckh M. Recent advances in the therapy and prevention of CMV infections. J Clin Virol 2000;16:25-40.
8. Boeckh M, Bowden R. Cytomegalovirus infection in marrow transplantation. Cancer Treat Res 1995;76: 97-136.
9. Boeckh M. Management of cytomegalovirus infections in blood and marrow transplant recipients. In: Antiviral Chemotherapy 5: New Directions for Clinical Applications and Research (Mills J, Volberding PA, Corey L, eds). Philadelphia: Plenum Publishing Company, 1999; pp80-109.
10. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261:3607-3609.
11. Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001;11:83-86.
12. Hart GD, Paya CV. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001;11:73-81.
13. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 2000;97:8039-8044.
14. Limaye A, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000;356:645-649.
15. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994;83:1971-1979.
16. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101: 407-414.
17. Razonable RR, van Cruijsen H, Brown RA, Wilson JA, Harmsen WS, Wiesner RH et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003;187:1801-1808.
18. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999;340:1462-1470.
19. Razonable RR, Brown RA, Hart GD, Wilson JA, Paya CV. Late onset cytomegalovirus (CMV) disease in solid organ transplant (SOT) recipients: Risk stratification based on serology, viral load and allograft status (abstract). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy(ICAAC), Chicago, Illinois, 2003. Abs tract V-1288.
20. Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R, Roberts NA. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis 2001;184:1598-1602.
21. Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004;189: 1615-1618.
22. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002;185:20-27.
23. Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF et al. Pre-emptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: A randomized, placebo-controlled trial. J Infect Dis 2002;185:854-860.
24. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999;190: 177-182.
25. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355:2032-2036.
26. Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997;176:1484-1490.
27. Cope AV, Sweny P, Sabin C, Rees L, Griffiths PD, Emery VC. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. J Med Virol 1997;52:200-205.
28. Emery VC. Viral dynamics during active cytomegalovirus infection and pathology. Intervirology 1999;42: 405-411.
29. Mattes FM, Hainsworth EG, Geretti AM, Nebbia G, Prentice G, Potter M et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant patients. J Infect Dis 2004;189:1355-1361.
30. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid organ transplant patients with CMV disease. J Infect Dis 2002;186:829-833.
31. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplant. J Infect Dis 2000;181:717-720.
32. Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol 2002;40:746-752.
33. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998;11: 533-554.
34. Boivin G, Belanger R, Delage R, Beliveau C, Demers C, Goyette N et al. Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation. J Clin Microbiol 2000;38:4356-4360.
35. Razonable RR, Brown RA, Espy MJ, Rivero A, Kremers W, Wilson J et al. Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems. J Clin Microbiol 2001;39:4472-4476.
36. Abecassis MM, Koffron AJ, Kaplan B, Buckingham M, Muldoon JP, Cribbins AJ et al. The role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? Transplantation 1997;63: 275-279.
37. Boivin G, Quirk MR, Kringstad BA, Germain M, Jordan MC. Early effects of ganciclovir therapy on the quantity of cytomegalovirus DNA in leukocytes of immunocompromised patients. Antimicrob Agents Chemother 1997;41:860-862.
38. Gerna G, Furione M, Baldanti F, Sarasini A. Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. J Clin Micobiol 1994;32:2709-2717.
39. Humar A, Gregson D, Caliendo AM, McGreer A, Malkan G, Krajden M et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999;68: 1305-1311.
40. Roberts TC, Brennan DC, Buller RS, Gaudreault-Keener M, Schnitzler MA, Sternhell KE et al. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients. J Infect Dis 1998;178:626-635.
41. Hebart H, Wuchter P, Loeffler J, Gscheidle B, Hamprecht K, Sinzger C et al. Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant. Bone Marrow Transplant 2001;28: 213-218.
42. Tong CY, Cuevas LE, Williams H, Bakran A. Comparison of two commercial methods for measurement of cytomegalovirus load in blood samples after renal transplantation. J Clin Microbiol 2000;38:1209-1213.
43. Boeckh M, Huang M, Ferrenberg J, Stevens-Ayers T, Stensland L, Nichols WG et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004;42: 1142-1148.
44. Mattes FM, Hainsworth EG, Hassan-Walker AF, Burroughs AK, Sweny P, Griffiths PD et al. Kinetics of cytomegaloviral load decline in solid organ transplant recipients after pre-emptive valganciclovir therapy. J Infect Dis 2004 (in press).
45. Razonable RR, Brown RA, Wilson J, Groettum C, Kremers W, Espy M et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 2002;73: 968-973.
46. Weinberg A, Schissel D, Giller R. Molecular methods for cytomegalovirus surveillance in bone marrow transplant recipients. J Clin Microbiol 2002;40:4203-4206.
47. Cortez KJ, Fischer SH, Fahle GA, Calhoun LB, Childs RW, Barrett AJ et al. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis 2003; 188:967-972.
48. Mengelle C, Sandres-Saune K, Pasquier C, Rostaing L, Mansuy JM, Marty M et al. Automated extraction and quantification of human cytomegalovirus DNA in whole blood by real-time PCR assay. J Clin Microbiol 2003; 41:3840-3845.
49. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant patients. Antimicrob Agents Chemother 2000;44: 2811-2815.
50. Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised host. Expert Rev Anti Infect Ther 2004;2:27-42.
51. Babel N, Gabdrakhmanova L, Juergensen JS, Eibl N, Hoerstrup J, Hammer M et al. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience. Transplantation 2004;78: 283-285.
52. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346:1119-1126.
53. Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000;2:112-117.
54. Winston DJ, Busuttil RW. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant patients. Transplantation 2003;75: 229-233.
55. Winston DJ, Busuttil RW. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 2004;77:305-308.
56. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B et al. Efficacy and safety of valganciclovir versus oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-620.
57. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;188: 173-178.
58. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993;118: 179-184.
59. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996;88: 4063-4071.
60. Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied NJ, Camara R et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group. Bone Marrow Transplant 1997;19:129-133.
61. Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied N, Fernandez Kanada JM et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994:343:749-753.
62. Ljungman P, de La Camara R, Milpied N, Volin L, Russell CA, Crisp A et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002;99:3050-3056.
63. Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Torrito MG, Valacyclovir Cytomegalovirus Study Group. Randomized comparison of oral valaciclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003;36:749-758.
64. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991;325: 1601-1607.
65. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997;90: 2502-2508.
66. Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992; 166:473-179.
67. Ljungman P, Oberg G, Aschan J, Ehrnst A, Lonnqvist B, Pauksen K et al. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996;18: 565-568.
68. Bregante S, Bertilson S, Tedone E, Van Lint MT, Trespi G, Mordini N et al. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. Bone Marrow Transplant 2000;26:23-29.
69. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Englehard D et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002;99:1159-1164.